A very recent publication indicates that tau phosphorylated at residue 217 (P-tau217) seems to perform better than the classical P-tau to identify patients with AD and might represent a better biomarker for the clinical diagnosis of the disease [101]. The gene discussed is MAPT; the disease is Alzheimer disease.